CovidResearchTrials by Shray Alag

CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)

ApixabanWiki

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (3)

Name (Synonyms) Correlation
drug1473 Intravenous sedation Wiki 1.00
drug1426 Inhaled sedation Wiki 1.00
drug1004 Enoxaparin Wiki 0.29

Correlated MeSH Terms (4)

Name (Synonyms) Correlation
D013577 Syndrome NIH 0.10
D055371 Acute Lung Injury NIH 0.10
D012127 Respiratory Distress Syndrome, Newborn NIH 0.09
D012128 Respiratory Distress Syndrome, Adult NIH 0.08

Correlated HPO Terms (0)

Name (Synonyms) Correlation

There is one clinical trial.

Clinical Trials

1 FREEDOM COVID Anticoagulation Strategy Randomized Trial

Coronavirus Disease (COVID-19), caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has led to unprecedented morbidity and mortality in the modern era. To date, nearly 13 million people have contracted COVID-19, leading to more than 550,000 deaths worldwide. As the number of affected individuals continues to climb, effective strategies for treatment and prevention of the disease are of paramount importance. SARS-CoV-2 is understood to directly invade cells via the human angiotensin-converting enzyme 2 (ACE2) receptor, which is expressed predominantly in the lungs but also throughout the cardiovascular system. Thus, while acute respiratory distress syndrome remains a feared complication, new thromboembolic disease has emerged as a common and potentially catastrophic manifestation of COVID-19.

NCT04512079 COVID-19 SARS-CoV-2 Drug: Enoxaparin Drug: Apixaban

Primary Outcomes

Description: The time to first event rate within 30 days of randomization of the composite of all-cause mortality, intubation requiring mechanical ventilation, systemic thromboembolism (including pulmonary emboli) confirmed by imaging or requiring surgical intervention OR ischemic stroke confirmed by imaging.

Measure: Time to first event

Time: 30 days

Description: Number of in-hospital rate of BARC 3 or 5 bleeding (binary). BARC Type 3: a. Overt bleeding plus hemoglobin drop of 3 to < 5 g/dL (provided hemoglobin drop is related to bleed); transfusion with overt bleeding b. Overt bleeding plus hemoglobin drop < 5 g/dL (provided hemoglobin drop is related to bleed); cardiac tamponade; bleeding requiring surgical intervention for control; bleeding requiring IV vasoactive agents c. Intracranial hemorrhage confirmed by autopsy, imaging, or lumbar puncture; intraocular bleed compromising vision. BARC Type 5: Probable fatal bleeding Definite fatal bleeding (overt or autopsy or imaging confirmation)

Measure: Number of in-hospital rate of BARC 3 or 5

Time: 30 days

Secondary Outcomes

Description: Myocardial infarction (according to the 4th universal definition, types 1,2, and 3)

Measure: Number of participants with Myocardial infarction

Time: 30 days after randomization

Description: Myocardial infarction (according to the 4th universal definition, types 1,2, and 3)

Measure: Number of participants with Myocardial infarction

Time: 90 days after randomization

Description: Deep vein thrombosis with confirmation on imaging

Measure: Number of participants with Deep Vein Thrombosis

Time: 30 days after randomization

Description: Deep vein thrombosis with confirmation on imaging

Measure: Number of participants with Deep Vein Thrombosis

Time: 90 days after randomization

Description: Intubation and mechanical ventilation

Measure: Number of participants requiring Ventilation

Time: 30 after randomization

Description: Intubation and mechanical ventilation

Measure: Number of participants requiring Ventilation

Time: 90 days after randomization

Description: All-cause death

Measure: Number of All Death

Time: 30 days after randomization

Description: All-cause death

Measure: Number of All Death

Time: 90 days after randomization

Description: Cause of Death

Measure: Cause of Death

Time: 30 days after randomization

Description: Cause of Death

Measure: Cause of Death

Time: 90 days after randomization

Description: Stroke confirmed by imaging or autopsy (all, ischemic and hemorrhagic)

Measure: Number of participants with Stroke

Time: 30 days after randomization

Description: Stroke confirmed by imaging or autopsy (all, ischemic and hemorrhagic)

Measure: Number of participants with Stroke

Time: 90 days after randomization

Description: Pulmonary emboli confirmed by imaging or autopsy

Measure: Number of participants with Pulmonary Emboli

Time: 30 days after randomization

Description: Pulmonary emboli confirmed by imaging or autopsy

Measure: Number of participants with Pulmonary Emboli

Time: 90 days after randomization

Description: Systemic thromboembolism confirmed by imaging or requiring surgical intervention

Measure: Number of participants with Systemic Thromboembolism

Time: 30 days after randomization

Description: Systemic thromboembolism confirmed by imaging or requiring surgical intervention

Measure: Number of participants with Systemic Thromboembolism

Time: 90 days after randomization

No related HPO nodes (Using clinical trials)